Promising clinical results for heavily pretreated patients with colorectal cancer
Patients with KRASG12C-mutant colorectal cancer treated with Adagrasib – a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it, when in active state. In this MEDtalk Jared Weiss, oncologist, presents the promising results of adagrasib treatment